Why Should You Attend:
Pharmacovigilance is an activity that permeates the use of any pharmaceutical (branded, generic, or over-the-counter), biological agent, vaccine, or medical device during both development and after marketing approval has been granted. There are a number of stakeholders in post-marketing drug safety: Sponsor staff, health care providers, health care payers, regulators, and most importantly, patients. Post marketing pharmacovigilance begins with the creation of the product's label. The label is a distillation of what is known about the safety and use of the product.
This webinar will start with consideration of pharmacovigilance from the moment that the label is completed. This webinar will:
Areas covered in the Webinar:
Who Will Benefit:
Dr. David E. Lilienfeld, is an internationally recognized authority in pharmacovigilance. During his more than two decades of experience in the pharmaceutical industry (contract research organizations, major pharmaceutical and small pharmaceutical companies, and start-ups), he has practiced pharmacovigilance as a safety physician, pharmacoepidemiology, and safety department head. He has written about drug safety issues and presented at numerous industry and professional society meetings on pharmacovigilance, and has served on the Board of Directors of the International Society for Pharmacoepidemiology, which he co-founded.
Pharmacovigilance is the surveillance for collection of data about assessment of, and prevention of adverse effects of pharmaceuticals, biological compounds, vaccines, and medical devices. During both clinical development and after marketing approval has been granted, it is the pharmacovigilance function under which collection and analyses takes place of information regarding adverse events, as well as their prevention using Risk Evaluation and Mitigation Strategies (REMS) programs.
While clinical safety concerns the collection, processing, and analysis of adverse event reports from investigators using the product in the tightly controlled setting of clinical research, post-marketing safety concerns these same activities in the context of how the product is actually used in the community. Distribution of the product is wider, and while some safety information from development programs are helpful, the clinical development setting does not allow for the detection of relatively infrequent events--a key component of post-marketing approval safety activities.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
PAYMENT METHOD: 100% Secure Transaction